Last reviewed · How we verify
parecoxib, valdecoxib, parecoxib and dexamethasone
Parecoxib and valdecoxib are selective COX-2 inhibitors that reduce prostaglandin synthesis to provide anti-inflammatory and analgesic effects.
Parecoxib and valdecoxib are selective COX-2 inhibitors that reduce prostaglandin synthesis to provide anti-inflammatory and analgesic effects. Used for Acute postoperative pain, Rheumatoid arthritis, Osteoarthritis.
At a glance
| Generic name | parecoxib, valdecoxib, parecoxib and dexamethasone |
|---|---|
| Sponsor | Asker & Baerum Hospital |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
These drugs selectively inhibit cyclooxygenase-2 (COX-2), an enzyme responsible for producing pro-inflammatory prostaglandins. By blocking COX-2 while sparing COX-1, they provide pain relief and reduce inflammation with potentially fewer gastrointestinal side effects than non-selective NSAIDs. When combined with dexamethasone (a corticosteroid), the anti-inflammatory effects are potentiated.
Approved indications
- Acute postoperative pain
- Rheumatoid arthritis
- Osteoarthritis
Common side effects
- Cardiovascular events (myocardial infarction, stroke)
- Gastrointestinal ulceration
- Renal dysfunction
- Hypertension
- Edema
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: